Reported positive (1)
- Malignant germ cell tumor of fallopian tube with rhabdomyosarcoma: a case report and literature review
Case report · Limited evidence · Sep 2023
Etoposide
Evidence at a glanceInsufficient evidenceMixed results⚠ Studies disagree
2 published studies tagged to this agent0 human studies approved & graded (trial, observational, or meta-analysis)
Why this grade?
Insufficient evidence — No primary experimental studies yet.
- 0 human · 0 animal · 0 lab · 2 review/other
- Most authoritative study: Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab
- Studies disagree on the reported direction (conflict flagged).
- No human studies yet
- Findings conflict across studies
- All studies are small (n < 30)
Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curatedetoposide
Educational only, not medical advice. OncoForge makes no claim that Etoposide treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 2 recent studies; not yet curated.
Research
Where the evidence is
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
CancerHuman evidenceMechanismSafetyTrial
Extrapulmonary Small Cell Carcinoma Of The Liver————
- Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab Case reportMixed results
Mixed Germ Cell Tumor Of Fallopian Tube————
- Malignant germ cell tumor of fallopian tube with rhabdomyosarcoma: a case report and literature review Case reportReported positive
Rhabdomyosarcoma————
- Malignant germ cell tumor of fallopian tube with rhabdomyosarcoma: a case report and literature review Case reportReported positive
Reported figures
What supports this page
The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.
Guideline0
Meta-analysis0
Systematic review0
Randomized trial0
Clinical trial0
Observational0
Case report2
Review0
Preclinical0
Other0
2 studies2 review/other
Tracking 2 published studies of Etoposide: 2 reviews/other.
Reported direction across studies: 1 positive, 1 mixed.
Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is absent so far.
These counts summarize what the studies reported; they are not a measure of whether Etoposide works.
Cancers named in these studies
extrapulmonary small cell carcinoma of the liver (1)mixed germ cell tumor of fallopian tube (1)rhabdomyosarcoma (1)
Conflicting evidence
Negative or mixed (1)
- Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab
Case report · Limited evidence · Mar 2025
All studies
Case reportMixed resultsLimited evidenceTier 3 · early humann = 1
Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab
Radiology case reports · Mar 2025 · case report
This is a single-patient case report of extrapulmonary small cell carcinoma of the liver in a 52-year-old woman. The patient received systemic chemotherapy with carboplatin and etoposide combined with durvalumab, had clinical improvement of symptoms, but died 10 months after starting chemoimmunotherapy. The authors note that optimal treatment for EPSCC is generally extrapolated from small cell lung cancer and that there is insufficient evidence to routinely recommend immunotherapy in this group.
Reported effects: tumor_dimensions, n=1 · time_to_death_after_starting_chemoimmunotherapy 10 mo, n=1
Studied with: carboplatin, etoposide, carboplatin + etoposide.
Key findings
- Diagnosis of EPSCC of the liver was made after biopsy and immunohistochemistry (positive for CKA1/A3, chromogranin, synaptophysin, CD56 and TTF-1).
- Abdominal MRI showed an enlarged liver secondary to a mass affecting segments IV, V, VI, VII and VIII of 16.9 × 9.4 cm.
- Systemic chemotherapy with carboplatin and etoposide plus durvalumab was started.
- There was clinical improvement of the symptoms after starting treatment.
- The patient died 10 months after starting chemoimmunotherapy treatment.
- Authors state that optimal treatment of EPSCC is generally extrapolated from small cell lung cancer and there is insufficient evidence to routinely recommend immunotherapy for EPSCC.
Limitations: Single-patient case report (n=1), so findings are not generalizable.; No control or comparator group to assess treatment effect.; No dosing, schedule, or detailed treatment toxicity information provided.; Cannot establish causality or efficacy from a single observational case.; EPSCC is rare and treatment recommendations are extrapolated from small cell lung cancer, limiting direct applicability..
This report describes use of carboplatin + etoposide chemotherapy combined with durvalumab in a patient with extrapulmonary small cell carcinoma of the liver.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Case reportReported positiveLimited evidenceTier 3 · early humann = 1
Malignant germ cell tumor of fallopian tube with rhabdomyosarcoma: a case report and literature review
Diagnostic pathology · Sep 2023 · case report and literature review
This is a case report of a 34-year-old woman with a mixed germ cell tumor of the fallopian tube that included high-grade rhabdomyosarcoma components. She underwent extensive surgical resection followed by three cycles of BEP chemotherapy and one cycle of EP; at regular follow-up her tumor markers and imaging were normal and tumor-free survival reached 24 months.
Reported effect: tumor_free_survival 24 mo, n=1
Studied with: BEP (Bleomycin + Etoposide + Cisplatin), EP (Etoposide + Cisplatin).
Key findings
- Patient: 34-year-old woman presented with abdominal pain.
- Surgery performed: transabdominal resection of large left tubal masses, pelvic lymph node dissection, abdominal paraaortic lymph node dissection, right ovarian cyst excision, greater omentectomy, and multipoint peritoneal biopsy.
- Pathology: hematoxylin-eosin (H&E) and immunohistochemical (IHC) staining used to characterize the tumor (mixed germ cell tumor with high-grade rhabdomyosarcoma component).
- Adjuvant chemotherapy: 3 cycles of BEP (Bleomycin + Etoposide + Cisplatin) and 1 cycle of EP (Etoposide + Cisplatin).
- Outcome: regular follow-up showed normal tumor markers and imaging, with tumor-free survival reaching 24 months.
Limitations: Single-patient case report — no control group and limited generalizability.; No dosing amounts/administration details for chemotherapy provided in the abstract.; Follow-up limited to 24 months as reported; longer-term outcomes beyond that are not reported in the abstract.; Outcomes from a single case cannot establish efficacy or safety of the treatment..
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
What changed recently
The latest additions to Etoposide's evidence base, and anything that's been retracted.
Recently added- Malignant germ cell tumor of fallopian tube with rhabdomyosarcoma: a case report and literature review Case report · added Jun 2026
- Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab Case report · added Jun 2026
Cancers where Etoposide reported positive results
Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
Preclinical only: lab / animal (2)
Mixed germ cell tumor of fallopian tube1 positive
Limitations: Single-patient case report — no control group and limited generalizability.; No dosing amounts/administration details for chemotherapy provided in the abstract.; Follow-up limited to 24 months as reported; longer-term outcomes beyond that are not reported in the abstract.; Outcomes from a single case cannot establish efficacy or safety of the treatment..
Cited positive studies (1)
Rhabdomyosarcoma1 positive
Limitations: Single-patient case report — no control group and limited generalizability.; No dosing amounts/administration details for chemotherapy provided in the abstract.; Follow-up limited to 24 months as reported; longer-term outcomes beyond that are not reported in the abstract.; Outcomes from a single case cannot establish efficacy or safety of the treatment..
Cited positive studies (1)
Evidence at a glance: Etoposide by cancer
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
No primary experimental studies yet.
Largest credible effect: time_to_death_after_starting_chemoimmunotherapy 10 mo, n=1 PMID 40129783
Most authoritative study: Extrapulmonary small cell carcinoma of the liver treated with chemotherapy and durvalumab
No human studies yet · Based on a single study.
Mixed germ cell tumor of fallopian tubeInsufficient evidenceReported positive
No primary experimental studies yet.
Largest credible effect: tumor_free_survival 24 mo, n=1 PMID 37660086
Most authoritative study: Malignant germ cell tumor of fallopian tube with rhabdomyosarcoma: a case report and literature review
No human studies yet · Based on a single study.
No primary experimental studies yet.
Largest credible effect: tumor_free_survival 24 mo, n=1 PMID 37660086
Most authoritative study: Malignant germ cell tumor of fallopian tube with rhabdomyosarcoma: a case report and literature review
No human studies yet · Based on a single study.
Dose: as studied, not a recommendation
These are doses as studied or reported, never a recommendation. The right amount of Etoposide depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
Doses reported in studies- Malignant germ cell tumor of fallopian tube with rhabdomyosarcoma: a case report and literature review 3 cycles of Bleomycin + Etoposide + Cisplatin (BEP) chemotherapy and 1 cycle of EP (Etoposide + Cisplatin) chemotherapy · Case report · Sep 2023
Trials studying Etoposide
Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.